Tipranavir

Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI) -resistant HIV-1 isolates with IC50s of 66-410 nM[1][2]. Tipranavir inhibits SARS-CoV-2 3CLpro activity[3].

Product Specifications

CAS Number

[174484-41-4]

Product Name Alternative

PNU-140690

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

HIV; HIV Protease; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Tipranavir.html

Purity

98.0

Solubility

DMSO : 200 mg/mL (ultrasonic) |Ethanol : ≥ 50 mg/mL

Smiles

O=C1C([C@H](CC)C2=CC=CC(NS(C3=CC=C(C(F)(F)F)C=N3)(=O)=O)=C2)=C(O)C[C@](CCC4=CC=CC=C4)(CCC)O1

Molecular Formula

C31H33F3N2O5S

Molecular Weight

602.66

Precautions

H315, H319, H320

References & Citations

[1]Aoki M, et al. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J Virol. 2012 Dec;86 (24) :13384-96.|[2]Li F, et al. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38 (5) :871-8.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.